CA2557520A1 - A method for stabilizing blood pressure in hemodialysis subjects - Google Patents
A method for stabilizing blood pressure in hemodialysis subjects Download PDFInfo
- Publication number
- CA2557520A1 CA2557520A1 CA002557520A CA2557520A CA2557520A1 CA 2557520 A1 CA2557520 A1 CA 2557520A1 CA 002557520 A CA002557520 A CA 002557520A CA 2557520 A CA2557520 A CA 2557520A CA 2557520 A1 CA2557520 A1 CA 2557520A1
- Authority
- CA
- Canada
- Prior art keywords
- receptor agonist
- blood pressure
- vasopressin
- subject
- hemodialysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
Abstract
The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.
Claims (13)
1. A method for reducing excess extracellular fluid in a subject undergoing hemodialysis comprising administering a V-1 receptor agonist to the subject in an effective amount and thereby maintaining blood pressure during hemodialysis in order to facilitate reducing excess extracellular fluid in the subject.
2. A method for stabilizing high blood pressure between hemodialysis treatments in a subject undergoing hemodialysis by reducing excess extracellular fluid by the method of claim 1.
3. A method for inhibiting interdialytic hypertension by regulating blood pressure by the method of claim 2.
4. A method for inhibiting intradialytic hypotension by regulating blood pressure by the method of claim 1.
5. The method of claim 1, wherein the V-1 receptor agonist is arginine vasopressin.
6. The method of claim 1, wherein the V-1 receptor agonist is lysine vasopressin.
7. The method of claim 1, wherein the V-1 receptor agonist is terlipressin.
8. The method of claim 1, wherein the V-1 receptor agonist is octapressin
9. The method of claim 1, wherein the V-1 receptor agonist is ornipressin
10. The method of claim 1, wherein the V-1 receptor agonist is an organic molecule selected from the group consisting of 3-beta-(2-thienyl)-L-alanine)-8-lysine-vasopressin, N-alpha-glycyl-glycyl-glycyl-[8-lysine]-vasopressin, and 1-deamino-6-carba-[8-arginine]-vasopressin.
11. The method of claim 1, wherein the effective amount of the V-1 receptor agonist is in a range of about 0.05 milliunits/kg/minute - 2.0 milliunits/kg/hr.
12. The method of claim 1, wherein the effective amount of the V-1 receptor agonist is about 0.3 milliunits/kg/minute.
13. The method of claim 1, wherein the subject is a human, non-human primate, rabbit, sheep, rat, dog, cat, pig, or mouse.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45060903P | 2003-02-26 | 2003-02-26 | |
| US60/450,609 | 2003-02-26 | ||
| PCT/US2004/006029 WO2004075783A2 (en) | 2003-02-26 | 2004-02-26 | A method for stabilizing blood pressure in hemodialysis subjects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2557520A1 true CA2557520A1 (en) | 2004-09-10 |
| CA2557520C CA2557520C (en) | 2011-09-13 |
Family
ID=32927674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2557520A Expired - Lifetime CA2557520C (en) | 2003-02-26 | 2004-02-26 | A method for stabilizing blood pressure in hemodialysis subjects |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US7183255B2 (en) |
| CA (1) | CA2557520C (en) |
| WO (1) | WO2004075783A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004075783A2 (en) * | 2003-02-26 | 2004-09-10 | Landry Donald W | A method for stabilizing blood pressure in hemodialysis subjects |
| JO2937B1 (en) | 2004-08-11 | 2016-03-15 | فيرينغ.بي.في | Peptidic Vasopressin Receptor Agonists |
| RU2415149C2 (en) * | 2006-02-10 | 2011-03-27 | Ферринг Б.В. | Peptide compounds |
| EP1984012B1 (en) | 2006-02-13 | 2015-12-30 | Ferring B.V. | Use of peptidic vasopressin receptor agonists |
| US9050286B2 (en) * | 2007-08-14 | 2015-06-09 | Ferring B.V. | Use of peptidic vasopression receptor agonists |
| WO2009045309A2 (en) * | 2007-09-28 | 2009-04-09 | Ferring B.V. | Use of v2 receptor antagonists in combination with vasopressinergic agonists |
| US7879069B2 (en) * | 2007-10-26 | 2011-02-01 | Global Monitors, Inc. | Anti-pooling vest for patients undergoing hemodialysis and in critical care |
| EA020959B1 (en) | 2009-06-08 | 2015-03-31 | Палатин Текнолоджиз, Инк. | Melanocortin receptor-specific peptides |
| US9177129B2 (en) * | 2012-06-27 | 2015-11-03 | Intel Corporation | Devices, systems, and methods for monitoring and asserting trust level using persistent trust log |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE457055B (en) * | 1986-08-18 | 1988-11-28 | Ferring Ab | TOPIC RADIATION GEL FOR MUKOSA CONTAINING VARIETY CONDUCTIVE SUBSTANCES |
| CA2180529A1 (en) * | 1994-11-17 | 1996-05-30 | John Blue | Hemoglobin therapy in hemodialysis |
| WO2004075783A2 (en) * | 2003-02-26 | 2004-09-10 | Landry Donald W | A method for stabilizing blood pressure in hemodialysis subjects |
-
2004
- 2004-02-26 WO PCT/US2004/006029 patent/WO2004075783A2/en active Application Filing
- 2004-02-26 CA CA2557520A patent/CA2557520C/en not_active Expired - Lifetime
- 2004-02-26 US US10/789,548 patent/US7183255B2/en not_active Expired - Lifetime
-
2007
- 2007-02-26 US US11/710,754 patent/US20070213259A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2557520C (en) | 2011-09-13 |
| WO2004075783A3 (en) | 2004-12-29 |
| US20040229798A1 (en) | 2004-11-18 |
| WO2004075783A2 (en) | 2004-09-10 |
| US7183255B2 (en) | 2007-02-27 |
| US20070213259A1 (en) | 2007-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matsumura et al. | Angiotensin II acts at AT1receptors in the nucleus of the solitary tract to attenuate the baroreceptor reflex | |
| Machado et al. | Mechanisms of angiotensin-(1–7)-induced inhibition of angiogenesis | |
| Kandalam et al. | Angiotensin II activates JAK2/STAT3 pathway and induces interleukin-6 production in cultured rat brainstem astrocytes | |
| Cesari et al. | Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases | |
| CA2557520A1 (en) | A method for stabilizing blood pressure in hemodialysis subjects | |
| ATE539751T1 (en) | USE OF BRIMONIDINE TO TREAT STRESS-ASSOCIATED CONDITIONS | |
| ATE390142T1 (en) | SYNERGISTIC COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS | |
| ATE462427T1 (en) | USE OF TREPROSTINIL TO TREAT NEUROPATHIC DIABETIC FOOT ULCERS | |
| MX2009004424A (en) | Neuronal exocytosis inhibiting peptides. | |
| DK0738262T3 (en) | New Heterocyclic Compounds | |
| RU2661109C2 (en) | Angiotensin in treating brain conditions | |
| BR0310047A (en) | 8-azaprostaglandin analogues as agents for intraocular pressure decrease | |
| Dale et al. | Antinociceptive action of hemopressin in experimental hyperalgesia | |
| Wright et al. | Aminopeptidase-induced elevations and reductions in blood pressure in the spontaneously hypertensive rat | |
| Sharma et al. | Nitric oxide inhibits the expression of AT1 receptors in neurons | |
| NZ610732A (en) | Novel angiotensin type 2 (at2) receptor agonists and uses thereof | |
| DD158238A5 (en) | METHOD FOR PRODUCING A NEW INHIBITOR FOR ANGIOTENSE CONVERTING ENZYME | |
| ATE463514T1 (en) | ANTAGONISTS OF THE INTERACTION BETWEEN FACTOR VIII AND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß) | |
| DE602004002394D1 (en) | (3-ä3 - '(2,4-BIS-TRIFLUOROMETHYL-BENZYL) - (5-ETHYL-PYRIMIDIN-2-YL) -AMINOÜ-PROPOXYU-PHENYL) ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHOD FOR THE TREATMENT OF METABOLIC DISORDERS | |
| DE60219614D1 (en) | 3, 7 THIAPROSTANSÄUREDERIVATE AS A MEANS FOR THE REDUCTION OF THE AUGENINNENDRUCKES | |
| ATE360424T1 (en) | 2,3,4,5-TETRAHYDROBENZO[FÖ]1,4ÖOXAZEPINE-5-CARBONIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S | |
| KR20160016872A (en) | Angiotensin peptides in treating marfan syndrome and related disorders | |
| Abramov et al. | Regulation of feeding by galnon | |
| IL117816A0 (en) | N-subsituted azaheterocyclic compounds their preparation and pharmaceutical compositions containing them | |
| Wright et al. | Use of aminopeptidase M as a hypotensive agent in spontaneously hypertensive rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |